KORU Medical Systems (NASDAQ:KRMD) Releases Earnings Results

KORU Medical Systems (NASDAQ:KRMD) posted its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01, Zacks reports. KORU Medical Systems had a negative net margin of 9.49% and a negative return on equity of 22.43%. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $10.90 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• CEO Linda Tharby announced her planned retirement effective June 30, 2026, with CCO Adam Kalbermatten named President on March 15 and set to become CEO on July 1, and Linda remaining as an advisor through year-end.
• KORU delivered strong financials with Q4 revenue of $10.9M (+23% YoY), full-year revenue of $41.1M (+22%), positive adjusted EBITDA (~$0.6M) and positive operating cash flow, ending 2025 with $8.9M cash.
• International momentum accelerated (Q4 international growth ~71%, full-year ~80%), and EU MDR clearance for the Freedom60 prefilled-syringe compatibility enables shipments into Europe and targets an estimated $50M addressable market.
• KORU is expanding beyond IG — received 510(k) clearance for RYSTIGGO (entry into infusion clinics), has 9 drugs on label and 9 active pipeline collaborations (including near-term vancomycin, deferoxamine, Phesgo), and guided 2026 revenue of $47.5–$50M with positive adjusted EBITDA and full-year positive cash flow.
• Headwinds include modest gross margin pressure from higher material costs, tariffs and geographic mix, a 30% decline in PST (pharma services & trials) revenue due to milestone timing, and a relatively modest year-end cash balance that could leave limited downside cushion if expected milestones or prefill conversions slip.

KORU Medical Systems Stock Performance

NASDAQ:KRMD traded down $0.15 during mid-day trading on Friday, hitting $4.16. The stock had a trading volume of 149,597 shares, compared to its average volume of 195,435. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $5.13 and a 200-day simple moving average of $4.79. The stock has a market capitalization of $192.78 million, a price-to-earnings ratio of -52.03 and a beta of 0.47. KORU Medical Systems has a 52 week low of $1.86 and a 52 week high of $6.61.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KRMD. Craig Hallum reiterated a “buy” rating and set a $7.00 price objective on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Canaccord Genuity Group lifted their target price on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KORU Medical Systems in a report on Thursday, January 22nd. Lake Street Capital increased their price target on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Monday, January 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, KORU Medical Systems currently has a consensus rating of “Hold” and an average price target of $6.13.

Institutional Investors Weigh In On KORU Medical Systems

Several large investors have recently made changes to their positions in KRMD. BNP Paribas Financial Markets lifted its holdings in shares of KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares during the period. Barclays PLC grew its holdings in KORU Medical Systems by 8.8% during the fourth quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after acquiring an additional 5,457 shares during the period. Invesco Ltd. raised its position in KORU Medical Systems by 24.8% in the fourth quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock worth $162,000 after acquiring an additional 5,546 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in KORU Medical Systems by 26.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after acquiring an additional 5,649 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in KORU Medical Systems by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock valued at $5,944,000 after acquiring an additional 16,062 shares during the last quarter. Institutional investors and hedge funds own 58.60% of the company’s stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.